Citations

Citations to this article as recorded by  

• Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma
  Michio Kimura, Shiori Yamada, Makiko Go, Satoshi Yasuda, Hidenori Toyoda, Eiseki Usami
  Journal of Oncology Pharmacy Practice.2026; 32(1): 24.     CrossRef
• The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt
  Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Tomotake Shirono, Etsuko Moriyama, Takumi Kawaguchi
  Internal Medicine.2026; 65(11): 1450.     CrossRef
• Optimizing Nutrition to Counter Sarcopenia in Hepatocellular Carcinoma: A Narrative Review of Mechanisms, Clinical Consequences, and Supportive Therapeutic Options
  Hiroki Tai, Asahiro Morishita, Tomoko Tadokoro, Kyoko Oura, Rie Yano, Mai Nakahara, Koji Fujita, Shima Mimura, Joji Tani, Miwa Tatsuta, Takashi Himoto, Hideki Kobara
  Nutrients.2026; 18(3): 494.     CrossRef
• Quality of life in patients with hepatocellular carcinoma: a bibliometric analysis
  Can Huang, Meng Chen, Yanfang Sun, Lin Zhang, Wei Liu
  Discover Oncology.2026;[Epub]     CrossRef
• Strategic drug sequencing in hepatocellular carcinoma in the era of chemo-diversity: maximizing the therapeutic benefit of lenvatinib
  Hideki Iwamoto, Shigeo Shimose, Hironori Koga, Takumi Kawaguchi
  Journal of Liver Cancer.2026; 26(1): 83.     CrossRef
• The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
  Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S
  Hepatology International.2025; 19(2): 261.     CrossRef
• Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
  Yuhang Chen, Suoyi Dai, Chien-shan Cheng, Lianyu Chen
  Journal of Hematology & Oncology.2024;[Epub]     CrossRef
• The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea
  Yuri Cho, Bo Hyun Kim, Joong-Won Park
  Clinical and Molecular Hepatology.2023; 29(1): 99.     CrossRef
• Telephone follow‐up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib
  Sayo Tsumura, Shigeo Shimose, Takashi Niizeki, Eri Kuboyama, Hideki Iwamoto, Masatoshi Tanaka, Etusko Moriyama, Tomotake Shirono, Kota Takaki, Yu Noda, Masahito Nakano, Mitsutoshi Inoue, Kazuki Tsustumi, Ryoko Kuromatsu, Hironori Koga, Kyoko Higuchi, Taku
  Journal of Gastroenterology and Hepatology.2023; 38(7): 1140.     CrossRef
• Correlation between branched-chain amino acids intake and total lymphocyte count in head and neck cancer patients: a cross-sectional study
  Yosua Yan Kristian, Rahmat Cahyanur, Yohannessa Wulandari, Wina Sinaga, Widjaja Lukito, Findy Prasetyawaty, Wiji Lestari
  BMC Nutrition.2023;[Epub]     CrossRef